Pharmacodynamic action and mechanism of volatile oil from Rhizoma Ligustici Chuanxiong Hort. on treating headache

被引:60
作者
Peng, Cheng [1 ,2 ]
Xie, Xiaofang [1 ]
Wang, Lan [2 ]
Guo, Li [1 ]
Hu, Tanlian [1 ]
机构
[1] Chengdu Univ Tradit Chines Med, Coll Pharm, Chengdu 610075, Peoples R China
[2] Key Lab Standardizat Chines Med, Minist Educ, Chengdu 610075, Peoples R China
关键词
Volatile oil from Rhizoma Ligustici Chuanxiong Hort. (CXVO); Rhizoma Ligustici Chuanxiong Hort. (CX); Headache;
D O I
10.1016/j.phymed.2008.10.010
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
The volatile oil from Rhizoma Ligustici Chuanxiong Hort. (CXVO) is likely to be the mainly active ingredient of Chuangxiong in curing headache. In this study, oral administration of CXVO (45.0, 90.0, and 135.0 mu l/kg) to mice significantly elevated the pain threshold in the hot-plate test and reduced the number of abdominal writhing caused by acetic acid. CXVO (90.0 and 135.0 mu l/kg) not only reduced locomotor activity, but also prolonged the sleeping time induced by sodium pentobarbital (35 mg/kg), and the number of mice with sleeping time over 1 min by sodium pentobarbital (25 mg/kg) was markedly enlarged by CXVO (45.0, 90.0, 135.0 mu l/kg) administration. The three doses of CXVO significantly increased the pain threshold of rabbits with headache due to hot radiation and the level of plasma ET of rats with headache due to nitroglycerin injection. Besides, for the nitroglycerin-induced headache rats, the c-fos gene expression in the brain stem and hypothalamus was remarkably inhibited and the level of plasma CGRP was reduced significantly after CXVO administration at both doses 90.0 and 135.0 mu g/kg. The latter dosage could also raise the level of plasma 5-HT markedly. The study suggests that CXVO acts probably as the active ingredient of Rhizoma Ligustici Chuanxiong Hort. (CX) on treating headache and has potential to be an agent for treating headache. (C) 2008 Elsevier GmbH. All rights reserved.
引用
收藏
页码:25 / 34
页数:10
相关论文
共 19 条
[1]  
CHAI MC, 1997, HENAN MED RES, V6, P16
[2]  
Chen Q, 1993, RES METHODOLOGY PHAR, P564
[3]  
*DRUG ADM MIN HLTH, 1994, COMP GUID PRINC PREC, P51
[4]  
HUANG PX, 2000, DIAGNOSIS TREATMENT, P2
[5]  
Li Z. L., 2003, INF TRAD CHIN MED, V20, P31
[6]  
LUO YM, 1996, J CHINESE TRADITIONA, V27, P456
[7]  
MAO YS, 1996, FOREIGN MED SCI SECT, V23, P77
[8]  
PENG C, 2000, CHINESE ACTA LAB ANI, V8, P112
[9]  
RUAN Q, 2003, J ZHEJIANG NORMAL U, V26, P173
[10]  
SHI LF, 1995, CHINESE J PHARM TOXI, V9, P57